Jazz Pharmaceuticals plc (JAZZ) is scheduled to present new clinical and translational data for Modeyso in H3 K27M-mutant diffuse midline glioma at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting taking place November 19-23 in Honolulu, Hawaii.
Modeyso received accelerated approval from the FDA for the treatment of adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy as recently as August of this year.
It is the first and only FDA-approved treatment for this extremely rare and aggressive brain tumor, which impacts an estimated 2,000 people in the U.S. annually, including many children and young adults.
The presentations at the upcoming SNO Annual Meeting will cover both clinical and preclinical research on Modeyso as well as new preclinical data featuring JZP3507 in central nervous system (CNS) tumors.
JAZZ has traded in the range of $95.49- $148.06 over the past year. The stock closed yesterday's trading at $133.19, up 1.55%
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.